AR073677A1 - Derivados ciclicos de benzimidazol activadores de proteinquinasas de amp, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de diabetes tipo ii, obesidad y otras enfermedades. - Google Patents
Derivados ciclicos de benzimidazol activadores de proteinquinasas de amp, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de diabetes tipo ii, obesidad y otras enfermedades.Info
- Publication number
- AR073677A1 AR073677A1 ARP090103683A ARP090103683A AR073677A1 AR 073677 A1 AR073677 A1 AR 073677A1 AR P090103683 A ARP090103683 A AR P090103683A AR P090103683 A ARP090103683 A AR P090103683A AR 073677 A1 AR073677 A1 AR 073677A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- aryl
- unsubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula estructural 1: o una sal farmacéuticamente aceptable del mismo, en el que: X está ausente o se selecciona entre; (24) -CH2-, (25) -CHF-, (26) -CF2-, (27) -S-, (28) -O-, (29) -O-CH2-, (30) -NH-, (31) -C(O)-, (32) -NHC(O)-, (33) -C(O)NH-, (34) -NHSO2-, (35) -SO2NH-, y (36) -CO2-, donde cada CH2 está sin sustituir o sustituido por 1 o 2 sustituyentes seleccionados entre: hidroxi, halogeno, NH2, alquilo C1-6, CO2H, CO2alquilo C1-6, COalquilo C1-6, fenilo y -CH2fenilo, y donde cada NH está sin sustituir o sustituido por 1 sustituyente seleccionado entre: alquilo C1-6, CO2H, CO2alquilo C1-6, COalquilo C1-6, fenilo y -CH2fenilo; Y se selecciona entre: (6) cicloalquilo C3 10, (7) cicloalquenilo C3-10, (8) cicloheteroalquilo C2-10, (9) cicloheteroalquenilo C2-10, (10) arilo, y (11) heteroarilo, donde el cicloalquilo, cicloalquenilo, cicloheteroalquilo, cicloheteroalquenilo, arilo y heteroarilo están sin sustituir o sustituidos por 1, 2, 3 o 4 sustituyentes seleccionados entre Rb se selecciona entre: (35) oxo, (36) -CN, (37) -(CH2)nCO2H, (38) -(CH2)nCO2Ri, (39) -(CH2)nOH, (40) -(CH2)nC(O)NHRg, (41) -(CH2)nNHC(O)alquilo C1-6, (42) -(CH2)nNHSO2Ri, (43) -(CH2)nSO2NHRg, (44) (CH2)nSO2NHC(O)Ri, (45) -(CH2)nSO2NHCO2Ri, (46) -(CH2)nSO2NHCON(Rg)2, (47) -(CH2)nC(O)NHSO2Ri, (48) -(CH2)nNHC(O)N(Rg)2, (49) -(CH2)ncicloalquil C3-10-CO2Re, (50) heteroarilo, (51) -cicloheteroalquenilo C2-10, y (52) -cicloheteroalquilo C2-10, donde cada CH2 está sin sustituir o sustituido por 1 o 2 sustituyentes seleccionados entre alquilo C1-6, -OH y -NH2, donde cada NH está sin sustituir o sustituido por 1 sustituyente seleccionado entre Rc, y donde cada alquilo, cicloalquilo, cicloheteroalquilo, cicloheteroalquenilo, arilo y heteroarilo está sin sustituir o sustituido por 1, 2, 3 o 4 sustituyentes seleccionados entre Rc; cada R1 y R2 se selecciona independientemente entre: (1) hidrogeno, (2) halogeno, (3) -CH, (4) -CF3, (5) -alquilo C1-6, (6) -alquenilo C2-6, (7) alquinilo C2-6, (8) -(CH2)pcicloalquilo C3-10, (9) (CH2)pcicIoaIquil C3-7-arilo, (10) -(CH2)pcicloalquil C3-7-heteroarilo, (11) -(CH2)pcicloalquenilo C4-10, (12) -(CH2)pcicloaIquenil C4-7-arilo, (13) -(CH2)pcicloalquenil C4-7-heteroarilo, (14) -(CH2)pcicloheteroalquilo C2-10, (15) -(CH2)pcicIoheteroaqueniIo C2-10, (16) -(CH2)parilo, (17) bifenilo, (18) -(CH2)pheteroarilo, (19) -alquenil C2-6-alquilo, (20) -alquenil C2-6-arilo, (21) -alquenil C2-6-heteroarilo, (22) -alquenil C2-6-cicloalquiIo C3-7, (23) -alquenil C2 6-cicloalquenilo C3-7, (24) -alquenil C2-6-cicloheteroalquilo C2-7, (25) -alquenil C2-6-cicloheteroalquenilo C2-7, (26) -alquinil C2-6-(CH2)1-3-O-arilo, (27) -alquinil C2-6-alquilo, (28) -alquinil C2-6-arilo, (29) -alquinil C2-6-heteroarilo, (30) -alquinil C2-6-cicloalquilo C3-7, (31) -alquinil C2-6-cicloalquenilo C3-7, (32) -alquinil C2-6 -cicloheteroalquilo C3-7, (33) -alquinil C2-6-cicloheteroalquenilo C2-7, y (34) -C(O)NH-(CH2)0-3fenilo, donde cada CH2 está sin sustituir o sustituido por 1 o 2 sustituyentes seleccionados entre: halogeno, CF3, -OH, -NH2, -alquilo C 1-6, -Oalquilo C1-6, -NHalquilo C1-6 y -N(alquilo C1-6)2, donde cada alquilo, alquenilo y alquinilo está sin sustituir o sustituido por 1, 2 o 3 sustituyentes seleccionados entre: halogeno, CF3, -OH, -NH2, -alquilo C1-6, -Oalquilo C1-6, -NHalquilo C1-6 y -N(alquilo y donde cada cicloalquilo, cicloalquenilo, cicloheteroalquilo, cicloheteroalquenilo, fenilo, arilo y heteroarilo está sin sustituir o sustituido por 1, 2, 3 o 4 sustituyentes seleccionados independientemente entre Ra, con la condicion de que al menos uno de solo uno de R1 y R2 se seleccione entre el grupo que consiste en: hidrogeno, halogeno, -CN, -CF3, -alquilo C1-6, -alquenilo C2-6 y -alquinilo C2-6, y con la condicion de que si R1 o R2 es hidrogeno, entonces al menos uno de R3 y R4 no sea hidrogeno; R3 y R4 cada uno de se selecciona independientemente entre: (5) hidrogeno, (6) halogeno, (7) -alquilo C1-6, (8) -alquenilo C2-6, (9) -alquinilo C2-6, (10) -cicloalquilo C3-10, (11) -cicloalquenilo C3-10, (12) arilo, (13) heteroarilo, (14) -CN, (15) -CF3, (16) -OH, (17) -Oalquilo C1-6, (18) -NH2, (19) -NHalquilo C1-6, (20) -N(alquilo C1-6)2, (21) -Salquilo C1-6, (22) -SOalquilo C1-6, (23) -SO2alquilo C1-6, (24) -NHSO2alquilo C1-6, (25) -NHC(O)alquilo C1-6, (26) -SO2NHalquilo C1-6, y (27) -C(O)NHalquilo C1-6; R5 se selecciona entre: (7) hidrogeno, (8) -alquilo C1-6, (9) -CH2CO2H, y (10) -CH2CO2alquilo C1-6; cada Ra se selecciona independientemente entre el grupo que consiste en: (1) halogeno, (2) oxo, (3) -(CH2)mOH, (4) (CH2)mN(Rj)2, (5) (CH2)mNO2, (6) (CH2)mCN, (7) -alquilo C1-6, (8) -(CH2)mCF3, (9) -(CH2)mOCF3, (10) -OCH2OaIquilo C1-6, (11) -OCH2-arilo, (12) -(CH2)mC(=N-OH)N(Rj)2, (13) -(CH2)mOalquilo C1-6, (14) -(CH2)mO-arilo, (15) -OCH2fenilo, (16) (CH2)mSalquilo C1-6, (17) (CH2)mS(O)alquilo C1-6, (18) -(CH2)mS(O)2alquilo C1-6, (19) -(CH2)mNHS(O)2alquilo C1-6, (20) -(CH2)mC(O)Rf, (21) (CH2)mC(O)N(Rj)2, (22) -(CH2)mN(Rj)C(O)Rf, (23) -(CH2)mN(Rj)C(O)N(Rj)2, (24) -(CH2)mCO2H, (25) -(CH2)mOC(O)H, (26) (CH2)mCO2Rf, (27) -(CH2)mOC(O)Rf, (28) -(CH2)mcicloalquilo C3-7, (29) -(CH2)mcicloalquenilo C3-7, (30) -(CH2),mcicloheteroaIquiIo C2-6, (31) -(CH2)mcicloheteroaIquenilo C2-6, (32) -(CH2)rnarilo, y (33) -(CH2)mheteroarilo, donde cada CH2 está sin sustituir o sustituido por 1 o 2 sustituyentes seleccionados entre: oxo, -(CH2)0-3OH, -CN, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -alquilo C1-6, -Oalquilo C1-6, halogeno, -CH2F, -CHF2, -CF3, -CO2H, -CO2alquilo C1-6, -cicloalquilo C3-7, fenilo, CH2fenilo, heteroarilo y CH2heteroarilo, y donde el alquilo, cicloalquilo, cicloheteroalquilo, fenilo, arilo y heteroarilo están sin sustituir o sustituidos por 1, 2, 3 o 4 sustituyentes seleccionados entre: oxo, -(CH2)0-3OH, -CN, -NH2, -NH(alquilo C1-6), -N(alquilo C1-6)2, -alquilo C1-6, -Oalquilo C1-6, halogeno, -CH2F, -CHF2, -CF3, -CO2H, -CO2alquilo C1-6, -cicloalquilo C3-7, fenilo, CH2fenilo, heteroarilo y CH2heteroarilo; cada Rb se selecciona independientemente entre: (14) hidrogeno, (15) -alquilo C1-6, (16) -cicloalquilo C3-6, (17) -cicloalquenilo C3-6, (18) -cicloheteroalquilo C3-6, (19) arilo, (20) heteroarilo, (21) halogeno, (22) -OH, (23) -NO2, (24) -NH2, (25) -NH(alquilo C1-6), (26) -N(alquilo C1-6)2, (27) -Oalquilo C1-6, (28) -(CH2)qCO2H, (29) -(CH2)qCO2alquilo C1-6, (30) -CF3, (31) -CN (32) -SO2alquilo C1-6, y (33) -(CH2)qCON(Re)2, donde cada CH2 está sin sustituir o sustituido por 1 o 2 halogenos, y donde cada alquilo, cicloalquilo, cicloalquenilo, cicloheteroalquilo, arilo y heteroarilo están sin sustituir o sustituidos por 1, 2 o 3 halogenos; cada Rc se selecciona independientemente entre: (21) halogeno, (22) oxo, (23) -(CH2)rOH, (24) -(CH2)rN(Re)2, (25) -(CH2)rCN, (26) -alquilo C1-6, (27) -CF3, (28) -alquil C1-6-OH, (29) -OCH2Oalquilo C1-6, (30) -(CH2)rOalquilo C1-6, (31) -OCH2arilo, (32) -(CH2)rSalquilo C1-6, (33) -(CH2)rC(O)Rf, (34) -(CH2)rC(O)N(Re)2, (35) -(CH2)rCO2H, (36) -(CH2)rCO2Rf, (37) -(CH2)rcicloalquilo C3-7, (38) -(CH2)rcicloheteroalquilo C2-6, (39) -(CH2)rarilo, y (40) -(CH2)rheteroarilo, donde cada CH2 está sin sustituir o sustituido por 1 o 2 sustituyentes seleccionados entre: oxo, -OH, -CN, -N(Rh)2, -alquilo C1-6, -Oalquilo C1-6, halogeno, -CHF2, -CHF2, -CF3, -CO2H, -CO2alquilo C1-6, -cicloalquilo C3-7 y heteroarilo, y donde el alquilo, cicloalquilo, cicloheteroalquilo, arilo y heteroarilo están sin sustituir o sustituidos por 1, 2, 3 o 4 sustituyentes seleccionados entre: oxo, -OH, -CN, -N(Rh)2, -alquilo C1-6, -Oalquilo C1-6, halogeno, -CHF2, -CHF2, -CF3, -CO2H, -CO2alquilo C1-6, -cicloalquilo C3-7 y heteroarilo; cada Re, Rg y Rh se selecciona independientemente entre: (1) hidrogeno, y (2) alquilo donde el alquilo está sin sustituir o sustituido por 1, 2, 3 o 4 sustituyentes seleccionados entre: -OH, oxo, halogeno, alquilo -Oalquilo C1-6, -NH2, -NH(alquilo C1-6) y -N(alquilo C1-6)2; cada Rj se selecciona independientemente entre: (1) hidrogeno, (2) alquilo C1-6, (3) cicloalquilo C3-6, (4) -C(O)Ri, y (5) -SO2Ri, donde el alquilo y el cicloalquilo están sin sustituir o sustituidos por 1, 2, 3 o 4 sustituyentes seleccionados entre: -OH, oxo, halogeno, alquilo C1-6, -Oalquilo C1-6, -NH2, -NH(alquilo C1-6) y -N(alquilo C1-6)2; cada Rf y Ri se selecciona independientemente entre: (19) alquilo C1-6, (20) cicloalquilo C4-7, (21) cicloalquenilo C4-7, (22) cicloheteroalquilo C3-7, (23) cicloheteroalquenilo C3-7, (24) arilo, y (25) heteroarilo, donde el alquilo, cicloalquilo, cicloalquenilo, cicloheteroalquilo, cicloheteroalquenilo, arilo y heteroarilo están sin sustituir o sustituidos por 1, 2, 3 o 4 sustituyentes seleccionados entre: oxo, -OH, -CN, -NH2, -alquilo C1-6, -Oalquilo C1-6, halogeno, -CH2F, -CHF2, -CF3, -CO2H, -CO2alquilo C1-6, -cicloalquilo C3-7 y heteroarilo; n es 0, 1, 2, 3 o 4; m es 0, 1, 2, 3 o 4; p es 0, 1, 2 o 3; q es 0, 1, 2, 3 o 4; y r es 0, 1 o 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19433708P | 2008-09-26 | 2008-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073677A1 true AR073677A1 (es) | 2010-11-24 |
Family
ID=41395799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103683A AR073677A1 (es) | 2008-09-26 | 2009-09-24 | Derivados ciclicos de benzimidazol activadores de proteinquinasas de amp, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de diabetes tipo ii, obesidad y otras enfermedades. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8394969B2 (es) |
EP (1) | EP3924343A1 (es) |
JP (1) | JP5764064B2 (es) |
CN (1) | CN102361857B (es) |
AR (1) | AR073677A1 (es) |
AU (1) | AU2009296820B2 (es) |
CA (1) | CA2737694C (es) |
MX (1) | MX2011003239A (es) |
TW (1) | TWI393709B (es) |
WO (1) | WO2010036613A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP2012507530A (ja) | 2008-10-29 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体 |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
CA2786314A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8344137B2 (en) * | 2010-04-14 | 2013-01-01 | Hoffman-La Roche Inc. | 3,3-dimethyl tetrahydroquinoline derivatives |
CN103209981B (zh) | 2010-09-10 | 2016-12-28 | 盐野义制药株式会社 | 具有ampk活化作用的杂环稠合咪唑衍生物 |
WO2012047772A2 (en) * | 2010-10-07 | 2012-04-12 | Schering Corporation | Imidazole derivatives |
WO2012064569A1 (en) * | 2010-11-08 | 2012-05-18 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
FR2968213B1 (fr) | 2010-12-03 | 2014-03-21 | Oreal | Utilisation d'une association amincissante |
AR084174A1 (es) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
PE20140859A1 (es) | 2011-02-25 | 2014-07-25 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos |
CA2837312A1 (en) * | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof |
CA2841906A1 (en) * | 2011-07-15 | 2013-01-24 | Shionogi & Co., Ltd. | Azabenzimidazole derivative having ampk-activating activity |
TWI449702B (zh) * | 2012-07-11 | 2014-08-21 | Merck Sharp & Dohme | 作為抗糖尿病劑之新穎環氮雜苯并咪唑衍生物 |
BR112015002080A2 (pt) | 2012-08-02 | 2017-07-04 | Merck Sharp & Dohme | composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença |
US9382243B2 (en) | 2012-08-22 | 2016-07-05 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydropyran derivatives |
WO2014031515A1 (en) * | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives |
WO2014031441A1 (en) * | 2012-08-22 | 2014-02-27 | Merck Sharp & Dohme Corp. | Novel benzimidazole tetrahydrofuran derivatives |
US9868733B2 (en) | 2012-08-22 | 2018-01-16 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydrofuran derivatives |
US9556193B2 (en) | 2012-08-22 | 2017-01-31 | Merck Shapr & Dohme Corp. | Benzimidazole hexahydrofuro[3,2-b]furan derivatives |
US9527839B2 (en) | 2012-08-22 | 2016-12-27 | Merck Sharp & Dohme Corp. | Benzimidazole tetrahydropyran derivatives |
US9890119B2 (en) | 2013-02-27 | 2018-02-13 | Shionogi & Co., Ltd. | Indole and azaindole derivative having AMPK-activating activity |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015073342A1 (en) | 2013-11-15 | 2015-05-21 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
EP3089748A4 (en) | 2014-01-02 | 2017-09-27 | Massachusetts Eye & Ear Infirmary | Treating ocular neovascularization |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
AU2015309863B2 (en) | 2014-08-27 | 2019-12-05 | Shionogi & Co., Ltd. | Azaindole derivative having AMPK-activating effect |
JPWO2016068099A1 (ja) * | 2014-10-28 | 2017-08-10 | 塩野義製薬株式会社 | Ampk活性化作用を有する複素環誘導体 |
WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
CN104961703A (zh) * | 2015-07-14 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 一类苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途 |
CN104961702A (zh) * | 2015-07-14 | 2015-10-07 | 佛山市赛维斯医药科技有限公司 | 苯并异恶唑类11β-HSD1抑制剂、制备方法及其用途 |
CN105596333A (zh) * | 2016-02-02 | 2016-05-25 | 白强 | 一种防治糖尿病及其并发症的药物组合物及其应用 |
EP3421467A4 (en) | 2016-02-26 | 2019-08-07 | Shionogi & Co., Ltd | 5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATION EFFECT |
JPWO2017200068A1 (ja) | 2016-05-20 | 2019-03-22 | 塩野義製薬株式会社 | Ampk活性化作用を有する5−置換ベンズイミダゾールおよび5−置換アザベンズイミダゾール誘導体 |
WO2018035128A1 (en) | 2016-08-19 | 2018-02-22 | Rigel Pharmaceuticals, Inc. | Benzimidazole direct ampk activators |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
CN108503632B (zh) * | 2018-06-26 | 2020-07-28 | 北京圣永制药有限公司 | 一种吲哚类衍生物及其在糖尿病中的应用 |
EP3956026B9 (en) | 2019-04-19 | 2023-10-04 | Sorbonne Universite | P16ink4a inhibitor for preventing or treating huntington's disease |
MX2022007164A (es) | 2019-12-13 | 2022-09-12 | Inspirna Inc | Sales metálicas y usos de estas. |
JP7441477B2 (ja) * | 2020-02-13 | 2024-03-01 | ▲勁▼方医▲薬▼科技(上海)有限公司 | ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用 |
AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
KR20230012597A (ko) | 2020-05-19 | 2023-01-26 | 칼리오페, 인크. | Ampk 활성화제 |
JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ,インク. | Ampkアクチベーター |
TW202329944A (zh) * | 2021-11-23 | 2023-08-01 | 美商克力歐普股份有限公司 | Ampk活化劑 |
CN117243950A (zh) * | 2023-10-31 | 2023-12-19 | 首都医科大学附属北京朝阳医院 | Mk-3903在制备预防和/或治疗缺血性心脏病的药物中的应用 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2472574A1 (fr) * | 1979-12-24 | 1981-07-03 | Ici Pharma | Derives de cephalosporine et composition pharmaceutique les contenant |
JPS57151944A (en) | 1981-03-16 | 1982-09-20 | Fuji Photo Film Co Ltd | Color photosensitive silver halide material |
JPS58193541A (ja) | 1982-05-07 | 1983-11-11 | Konishiroku Photo Ind Co Ltd | 熱現像画像記録材料 |
JPH0245181B2 (ja) | 1983-03-16 | 1990-10-08 | Fuji Photo Film Co Ltd | Netsugenzokaraakankozairyo |
GB8313320D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Coating compositions |
GB8313321D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Preparation of mercaptan substituted carboxylic acids |
GB8313322D0 (en) | 1983-05-14 | 1983-06-22 | Ciba Geigy Ag | Heterocyclic-(cyclo)aliphatic carboxylic acids |
GB8412065D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Preparation of carboxylic acid derivatives |
GB8412064D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Compositions containing heterocyclic corrosion inhibitors |
GB8412063D0 (en) | 1984-05-11 | 1984-06-20 | Ciba Geigy Ag | Compositions containing heterocyclic corrosion inhibitors |
GB8525452D0 (en) * | 1985-10-16 | 1985-11-20 | Fisons Plc | Biologically active nitrogen heterocycles |
EP0232937B1 (en) * | 1986-02-03 | 1992-08-19 | Janssen Pharmaceutica N.V. | Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines |
WO1988002367A1 (en) * | 1986-09-27 | 1988-04-07 | Fisons Plc | Compounds |
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
CA1317939C (en) * | 1987-07-01 | 1993-05-18 | Janssen Pharmaceutica Naamloze Vennootschap | ¬(bicyclic heterocyclyl)methyl and -hetero| substituted hexahydro-1h-azepines and pyrrolidines |
US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
JPH08502484A (ja) | 1992-10-14 | 1996-03-19 | メルク エンド カンパニー インコーポレーテッド | フィブリノゲンリセプタ拮抗剤 |
JPH06298731A (ja) | 1993-04-13 | 1994-10-25 | Fuji Photo Film Co Ltd | 複素環化合物の製造方法 |
DE4326151A1 (de) | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
US5945425A (en) | 1994-04-29 | 1999-08-31 | G.D. Searle & Co. | Method of using (H+ /K+)ATPase inhibitors as antiviral agents |
DE69530488T2 (de) | 1994-06-30 | 2004-04-01 | Minnesota Mining And Mfg. Co., St. Paul | Zahnabdruckmaterial, das einen farbstoff zur sichtbarmachung der härtung enthält |
JPH09227854A (ja) | 1996-02-26 | 1997-09-02 | Toyo Ink Mfg Co Ltd | 感エネルギー線酸発生剤、感エネルギー線酸発生剤組成物、硬化性組成物およびその硬化物 |
WO1998008818A1 (en) | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
BR9810745A (pt) | 1997-06-10 | 2001-03-13 | Glaxo Group Ltd | Derivados de benzimidazol |
AU3297099A (en) | 1998-02-25 | 1999-09-15 | Genetics Institute Inc. | Inhibitors of phospholipase a2 |
JP4741725B2 (ja) | 1998-03-06 | 2011-08-10 | メタベイシス・セラピューティクス・インコーポレーテッド | リン含有化合物のための新規なプロドラッグ |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
WO2000003997A1 (fr) | 1998-07-15 | 2000-01-27 | Teijin Limited | Derives de thiobenzimidazole |
NZ510308A (en) | 1998-09-09 | 2003-06-30 | Metabasis Therapeutics Inc | Heteroaromatic alkylene substituted phosphonate derivatives useful as inhibitors of Fructose 1,6-bisphosphatase |
SE9900211D0 (sv) * | 1999-01-25 | 1999-01-25 | Pharmacia & Upjohn Ab | New compounds |
JP5063837B2 (ja) | 1999-03-05 | 2012-10-31 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 新規リン含有プロドラッグ |
NZ530833A (en) * | 1999-06-30 | 2005-08-26 | Tularik Inc | Compounds for the modulation of PPARgamma activity |
ES2225231T3 (es) | 1999-10-06 | 2005-03-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas. |
IL150565A0 (en) | 2000-01-17 | 2003-02-12 | Teijin Ltd | Benzimidazole derivatives and pharmaceutical compositions containing the same |
AU783839B2 (en) | 2000-01-17 | 2005-12-15 | Teijin Limited | Human chymase inhibitors |
DE60118748T2 (de) * | 2000-07-04 | 2007-05-16 | Kyoyu Agri Co., Ltd., Kawasaki | Benzoxazolverbindungen, verfahren zu ihrer herstellung und herbizide |
JP4734705B2 (ja) | 2000-10-31 | 2011-07-27 | 三菱化学株式会社 | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
US6969712B2 (en) * | 2000-11-15 | 2005-11-29 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
CN1520314A (zh) | 2001-08-24 | 2004-08-11 | 帝人株式会社 | 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物 |
FR2829765A1 (fr) | 2001-09-14 | 2003-03-21 | Lipha | Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique |
SE0104331D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Novel compounds |
CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
JP2004067629A (ja) | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
CA2502356A1 (en) | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
FR2846656B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
JP2006518738A (ja) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ,インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
EP1626717A4 (en) * | 2003-05-09 | 2009-09-09 | Merck & Co Inc | BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS |
US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
WO2005002520A2 (en) | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
GT200400136A (es) * | 2003-07-30 | 2005-05-02 | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular. | |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
US20050148643A1 (en) | 2003-08-19 | 2005-07-07 | Agouron Pharmaceuticals, Inc. | Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme |
US20070032466A1 (en) | 2003-08-22 | 2007-02-08 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US20050107374A1 (en) | 2003-10-21 | 2005-05-19 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
CA2543707A1 (en) * | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
EP1692113B1 (en) | 2003-11-14 | 2017-09-27 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
CN1922151A (zh) | 2004-02-12 | 2007-02-28 | 特兰斯泰克制药公司 | 取代的吡咯衍生物、组合物和使用方法 |
US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
US7097961B2 (en) | 2004-05-17 | 2006-08-29 | Agfa Gevaert | Stabilizers for use in substantially light-insensitive thermographic recording materials |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
WO2005121132A1 (ja) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | 抗hcv作用を有する縮合ヘテロ環化合物 |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
EP1807452B1 (en) | 2004-11-02 | 2013-05-08 | DSM IP Assets B.V. | Additive for uv-sunscreen preparations |
US8003806B2 (en) | 2004-11-12 | 2011-08-23 | OSI Pharmaceuticals, LLC | Integrin antagonists useful as anticancer agents |
WO2006078907A1 (en) * | 2005-01-20 | 2006-07-27 | Amgen Inc. | 2-substituted benzimidazole derivatives as vanilloid receptor ligands and their use in treatments |
WO2006094209A2 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-benzimidazolylalkyl-substituted amide sirtuin modulators |
ZA200707896B (en) | 2005-03-14 | 2009-07-29 | High Point Pharma Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
CN101273022A (zh) | 2005-07-04 | 2008-09-24 | 雷迪博士实验室有限公司 | 作为ampk激活剂的噻唑衍生物 |
WO2007007463A1 (ja) | 2005-07-11 | 2007-01-18 | Idemitsu Kosan Co., Ltd. | 電子吸引性置換基を有する含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
US20090278115A1 (en) | 2005-07-11 | 2009-11-12 | Idemitsu Kosan Co., Ltd. | Nitrogen-containing heterocyclic derivative and organic electroluminescence element using the same |
JP2007039406A (ja) | 2005-08-05 | 2007-02-15 | Idemitsu Kosan Co Ltd | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
CA2631732C (en) * | 2005-12-02 | 2012-12-18 | Bayer Healthcare Llc | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
JP2007153778A (ja) | 2005-12-02 | 2007-06-21 | Idemitsu Kosan Co Ltd | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
EP1976835A2 (en) | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2007095124A2 (en) | 2006-02-10 | 2007-08-23 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
PL1986633T3 (pl) | 2006-02-10 | 2015-01-30 | Summit Oxford Ltd | Leczenie dystrofii mięśniowej Duchenne'a |
FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2049526A2 (en) | 2006-07-14 | 2009-04-22 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
WO2008031016A2 (en) * | 2006-09-08 | 2008-03-13 | The Regents Of The University Of California | Heterocyclic ligands for integrin imaging and therapy |
WO2008051533A2 (en) * | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
TW200840110A (en) | 2006-11-20 | 2008-10-01 | Idemitsu Kosan Co | Organic electroluminescent device |
CN101674827A (zh) * | 2007-03-02 | 2010-03-17 | 先灵公司 | 苯并咪唑衍生物及其使用方法 |
EP2170396B1 (en) | 2007-08-03 | 2016-12-21 | Summit Corporation Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
JP5525456B2 (ja) | 2008-02-04 | 2014-06-18 | マーキュリー セラピューティクス,インコーポレイテッド | Ampk調節因子 |
UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
-
2009
- 2009-09-21 MX MX2011003239A patent/MX2011003239A/es active IP Right Grant
- 2009-09-21 AU AU2009296820A patent/AU2009296820B2/en active Active
- 2009-09-21 WO PCT/US2009/057686 patent/WO2010036613A1/en active Application Filing
- 2009-09-21 EP EP09792782.6A patent/EP3924343A1/en active Pending
- 2009-09-21 CN CN200980147275.5A patent/CN102361857B/zh active Active
- 2009-09-21 JP JP2011529149A patent/JP5764064B2/ja active Active
- 2009-09-21 CA CA2737694A patent/CA2737694C/en active Active
- 2009-09-21 US US12/563,782 patent/US8394969B2/en active Active
- 2009-09-24 TW TW098132353A patent/TWI393709B/zh not_active IP Right Cessation
- 2009-09-24 AR ARP090103683A patent/AR073677A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW201016672A (en) | 2010-05-01 |
TWI393709B (zh) | 2013-04-21 |
AU2009296820B2 (en) | 2014-03-20 |
CN102361857B (zh) | 2015-09-16 |
JP5764064B2 (ja) | 2015-08-12 |
CA2737694A1 (en) | 2010-04-01 |
WO2010036613A1 (en) | 2010-04-01 |
JP2012503661A (ja) | 2012-02-09 |
WO2010036613A8 (en) | 2010-11-18 |
AU2009296820A1 (en) | 2010-04-01 |
MX2011003239A (es) | 2011-04-28 |
US20100081643A1 (en) | 2010-04-01 |
US8394969B2 (en) | 2013-03-12 |
CN102361857A (zh) | 2012-02-22 |
EP3924343A1 (en) | 2021-12-22 |
CA2737694C (en) | 2013-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073677A1 (es) | Derivados ciclicos de benzimidazol activadores de proteinquinasas de amp, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de diabetes tipo ii, obesidad y otras enfermedades. | |
AR060054A1 (es) | Inhibidores de c-met protein quinasas. composiciones farmaceuticas. | |
AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
AR066348A1 (es) | Inhibidores de las iap | |
AR072913A1 (es) | Naftiridinas sustituidas y su utilizacion como medicamento | |
AR084408A1 (es) | Compuestos de purina y 7-deazapurina substituidos | |
PE20150132A1 (es) | Compuestos d-aminoacidos para enfermedad hepatica | |
ES2606197T3 (es) | Moduladores pirrolidina de GPR40 | |
CO5611167A2 (es) | Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c | |
GT200600295AA (es) | Una formulacion solida de dosificacion farmaceutica (patente fraccionaria derivada de la solicitud de patente no. pi-2006-295) | |
AR054232A1 (es) | Derivados de piridina -2- carboxamida como antagonistas de mglur5 | |
CL2008003384A1 (es) | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
AR055606A1 (es) | Derivados de benzoquinazolina | |
ATE482204T1 (de) | Sulfimide als proteinkinaseinhibitoren | |
AR063943A1 (es) | Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer. | |
AR051293A1 (es) | Inhibidores bace | |
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
PE20080123A1 (es) | Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c | |
AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
RU2008139905A (ru) | Фармацевтическая композиция для наружного применения | |
AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
GT200600086A (es) | Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
AR065280A1 (es) | Agentes antiparasitarios | |
AR054363A1 (es) | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 | |
AR048065A1 (es) | Compuestos de piperazina acetilinica y su uso como antagonistas del receptor de glutamato metabotropico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |